Abstract
INTRODUCTION We examined whether sex modifies the association between APOE ε2 and cognitive decline across two independent samples.
METHODS We used observational data from non-Hispanic White (NHW) and non-Hispanic Black (NHB) cognitively unimpaired adults. Linear mixed models examined interactive associations of APOE genotype (ε2 or ε4 carrier vs. ε3/ε3) and sex on cognitive decline in NHW and NHB participants separately.
RESULTS In both Sample 1 (N=9,766) and Sample 2 (N=915), sex modified the association between APOE ε2 and cognitive decline in NHW participants. Specifically, relative to APOE ε3/ε3, APOE ε2 protected against cognitive decline in men but not women. Among APOE ε2 carriers, men had slower decline than women. Among APOE ε3/ε3 carriers, cognitive trajectories did not differ between sexes. There were no sex-specific associations of APOE ε2 with cognitive decline in NHB participants (N=2,010).
DISCUSSION In NHW adults, APOE ε2 may selectively protect men against cognitive decline.
Competing Interest Statement
JAS: Scientific Advisory Board/Consultant: AVID radiopharmaceuticals (subsidiary of Lilly), Alnylam Pharmaceuticals, Apellis Pharmaceuticals, Takeda Pharmaceuticals, National Hockey League ASPL: Sat on a paid advisory board for Eisai within the past 12 months.
Funding Statement
This study did not receive funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Board of Sunnybrook Research Institute gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used in the present study (i.e., NACC, ROS/MAP/MARS, ADNI, and Prevent-AD cohorts) is available upon separate requests by investigators to the relevant institutions for each data source.
